BR112016028924A2 - composição farmacêutica que combina um anticonvulsivante e um derivado de ácido nicotínico - Google Patents
composição farmacêutica que combina um anticonvulsivante e um derivado de ácido nicotínicoInfo
- Publication number
- BR112016028924A2 BR112016028924A2 BR112016028924A BR112016028924A BR112016028924A2 BR 112016028924 A2 BR112016028924 A2 BR 112016028924A2 BR 112016028924 A BR112016028924 A BR 112016028924A BR 112016028924 A BR112016028924 A BR 112016028924A BR 112016028924 A2 BR112016028924 A2 BR 112016028924A2
- Authority
- BR
- Brazil
- Prior art keywords
- clg
- combination
- anticonvulsant
- pharmaceutical composition
- acid derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a combinação de gabapentina com clonixinato de lisina (clg) permite aliviar a dor neuropática de origem associada tanto à neuropatia diabética quanto a uma lesão nervosa. a combinação clg produz uma sinergia no efeito antialodínico, quando a alodinia é gerada por um dano mecânico direto ao tecido nervoso ou quando é produzido como consequência de uma patologia diabética. o efeito terapêutico da combinação clg é de 3 a 11 vezes maior que o efeito de cada um dos fármacos separadamente. a combinação de clg é segura uma vez que não apresenta efeitos adversos na atividade motora, nem alterações nos parâmetros neurológicos, tampouco dano em nível hepático ou renal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2014/000091 WO2015194926A1 (es) | 2014-06-16 | 2014-06-16 | Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016028924A2 true BR112016028924A2 (pt) | 2017-08-22 |
Family
ID=54935825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016028924A BR112016028924A2 (pt) | 2014-06-16 | 2014-06-16 | composição farmacêutica que combina um anticonvulsivante e um derivado de ácido nicotínico |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9895362B2 (pt) |
| EP (1) | EP3156051B1 (pt) |
| BR (1) | BR112016028924A2 (pt) |
| CA (1) | CA2951987C (pt) |
| CR (1) | CR20160573A (pt) |
| ES (1) | ES2709758T3 (pt) |
| MX (1) | MX344937B (pt) |
| WO (1) | WO2015194926A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000053225A1 (en) | 1999-03-10 | 2000-09-14 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| EP1940380A2 (en) | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| WO2007083985A1 (es) | 2006-01-19 | 2007-07-26 | Farmacéuticos Rayere, S.A. | Composición farmacéutica sinergística de diclofenaco y clonixinato de lisina |
| WO2007148950A1 (es) | 2006-06-20 | 2007-12-27 | Farmacéuticos Rayere, S.A. | Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina |
| WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
-
2014
- 2014-06-16 ES ES14894818T patent/ES2709758T3/es active Active
- 2014-06-16 WO PCT/MX2014/000091 patent/WO2015194926A1/es active Application Filing
- 2014-06-16 CA CA2951987A patent/CA2951987C/en active Active
- 2014-06-16 BR BR112016028924A patent/BR112016028924A2/pt not_active Application Discontinuation
- 2014-06-16 US US15/319,287 patent/US9895362B2/en active Active
- 2014-06-16 EP EP14894818.5A patent/EP3156051B1/en active Active
- 2014-06-16 CR CR20160573A patent/CR20160573A/es unknown
- 2014-06-16 MX MX2015003519A patent/MX344937B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2951987C (en) | 2017-10-24 |
| EP3156051A4 (en) | 2018-01-03 |
| MX2015003519A (es) | 2016-03-15 |
| CR20160573A (es) | 2017-03-14 |
| WO2015194926A1 (es) | 2015-12-23 |
| US9895362B2 (en) | 2018-02-20 |
| CA2951987A1 (en) | 2015-12-23 |
| EP3156051A1 (en) | 2017-04-19 |
| ES2709758T3 (es) | 2019-04-17 |
| MX344937B (es) | 2017-01-11 |
| EP3156051B1 (en) | 2018-11-07 |
| US20170151223A1 (en) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| PH12015501352A1 (en) | Compositions and methods that utilize a peptide tag that binds to hyaluronan | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| EA201491857A1 (ru) | АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ | |
| BR112017003571A2 (pt) | terapia combinada | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| CY1119505T1 (el) | ΚΑΜΣΥΛΙΚΟ ΑΛΑΣ (1r,1'R,4R)-4-MEΘOΞY-5"-MEΘYΛ-6'-[5-(ΠΡΟΠ-1-ΥΝ-1-ΥΛ)ΠΥΡΙΔΙΝ-3-ΥΛ]-3Ή-ΔΙΣΠΙΡΟ[ΚΥΚΛΟΕΞΑΝ-1,2',-ΙΝΔΕΝ-1'2'-ΙΜΙΔΑΖΟΛ]-4"-ΑΜΙΝΗΣ ΚΑΙ ΚΡΥΣΤΑΛΛΙΚΕΣ ΜΟΡΦΕΣ ΑΥΤΟΥ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΩΝ ΠΑΘΟΛΟΓΙΩΝ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΜΕ Α[ΒΕΤΑ], ΟΠΩΣ Π.Χ., Η ΝΟΣΟΣ ALZHEIMER | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| BR112016028918A2 (pt) | tratamento de hipertrigliceridemia grave | |
| AU2018253538A1 (en) | Levodopa formulations for rapid relief of parkinson's disease | |
| BR112015023694A2 (pt) | entrega craniana de fármacos | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| BR112014002407A2 (pt) | método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| BR112016028924A2 (pt) | composição farmacêutica que combina um anticonvulsivante e um derivado de ácido nicotínico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |